Prevention of nosocomial Staphylococcus aureus infections after rapid detection and eradication of S. aureus carriage in patients at risk: a randomised placebo controlled multi-center trial
Completed
- Conditions
- osocomial Staphylococcus aureus infectionInfections and InfestationsStreptococcus and staphylococcus as the cause of diseases classified to other chapters
- Registration Number
- ISRCTN56186788
- Lead Sponsor
- Erasmus Medical Centre (Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 1800
Inclusion Criteria
1. Adult patients (greater than or equal to 18 years)
2. Rapid detection positive for S. aureus nasal carriage
3. Expected admission of greater than or equal to 4 days
4. Treatment can be started less than or equal to 24 hours after admission
5. Informed consent
Exclusion Criteria
1. S. aureus infection at enrolment
2. Allergy to mupirocin
3. Allergy to chlorhexidin
4. Pregnancy or lactation
5. Recent (less than 4 weeks) mupirocin use
6. Nasal corpus alienum
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method osocomial S. aureus infection until 6 weeks after discharge according to Centers for Disease Control and prevention (CDC)-criteria.
- Secondary Outcome Measures
Name Time Method 1. Duration of hospital stay<br>2. In-hospital mortality<br>3. Time to nosocomial S. aureus infection